The price-to-earnings ratio for Zimmer Biomet Holdings Inc (NYSE: ZBH) is above average at 20.67x. The 36-month beta value for ZBH is also noteworthy at 0.73. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 6 rating it as “overweight,” 16 rating it as “hold,” and 1 rating it as “sell.”
The public float for ZBH is 197.57M, and at present, short sellers hold a 2.79% of that float. The average trading volume of ZBH on June 13, 2025 was 2.29M shares.
ZBH) stock’s latest price update
The stock of Zimmer Biomet Holdings Inc (NYSE: ZBH) has decreased by -1.04 when compared to last closing price of 94.24. Despite this, the company has experienced a 1.46% gain in its stock price over the last five trading sessions. zacks.com reported 2025-06-04 that Zimmer (ZBH) reported earnings 30 days ago. What’s next for the stock?
ZBH’s Market Performance
ZBH’s stock has risen by 1.46% in the past week, with a monthly drop of -4.34% and a quarterly drop of -13.30%. The volatility ratio for the week is 1.48% while the volatility levels for the last 30 days are 1.32% for Zimmer Biomet Holdings Inc The simple moving average for the past 20 days is -0.14% for ZBH’s stock, with a -11.15% simple moving average for the past 200 days.
Analysts’ Opinion of ZBH
Many brokerage firms have already submitted their reports for ZBH stocks, with JP Morgan repeating the rating for ZBH by listing it as a “Overweight.” The predicted price for ZBH in the upcoming period, according to JP Morgan is $128 based on the research report published on December 17, 2024 of the previous year 2024.
Piper Sandler gave a rating of “Neutral” to ZBH, setting the target price at $115 in the report published on July 01st of the previous year.
ZBH Trading at -4.37% from the 50-Day Moving Average
After a stumble in the market that brought ZBH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.09% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZBH starting from Yi Sang, who proposed sale 1,000 shares at the price of $95.00 back on Jun 11 ’25. After this action, Yi Sang now owns shares of Zimmer Biomet Holdings Inc, valued at $95,000 using the latest closing price.
Winkler Lori, the SVP and CHRO of Zimmer Biomet Holdings Inc, sale 1,443 shares at $104.40 during a trade that took place back on Mar 05 ’25, which means that Winkler Lori is holding 8,768 shares at $150,649 based on the most recent closing price.
Stock Fundamentals for ZBH
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.71 for the gross margin
The net margin for Zimmer Biomet Holdings Inc stands at 0.12. The total capital return value is set at 0.07. Equity return is now at value 7.31, with 4.19 for asset returns.
Based on Zimmer Biomet Holdings Inc (ZBH), the company’s capital structure generated 0.37 points at debt to capital in total, while cash flow to debt ratio is standing at 0.23. The debt to equity ratio resting at 0.58. The interest coverage ratio of the stock is 5.62.
Currently, EBITDA for the company is 2.25 billion with net debt to EBITDA at 2.52. When we switch over and look at the enterprise to sales, we see a ratio of 3.15. The receivables turnover for the company is 5.02for trailing twelve months and the total asset turnover is 0.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.44.
Conclusion
In summary, Zimmer Biomet Holdings Inc (ZBH) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
